328 related articles for article (PubMed ID: 15793255)
1. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.
Knowler WC; Hamman RF; Edelstein SL; Barrett-Connor E; Ehrmann DA; Walker EA; Fowler SE; Nathan DM; Kahn SE;
Diabetes; 2005 Apr; 54(4):1150-6. PubMed ID: 15793255
[TBL] [Abstract][Full Text] [Related]
2. [Progress in the prevention of type 2 diabetes].
Schernthaner G
Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
[TBL] [Abstract][Full Text] [Related]
3. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
The Diabetes Prevention Program Research Group
Diabetes Care; 1999 Apr; 22(4):623-34. PubMed ID: 10189543
[TBL] [Abstract][Full Text] [Related]
4. An update on the Diabetes Prevention Program.
Ratner RE;
Endocr Pract; 2006; 12 Suppl 1(Suppl 1):20-4. PubMed ID: 16627375
[TBL] [Abstract][Full Text] [Related]
5. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
6. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.
Franks PW; Jablonski KA; Delahanty L; Hanson RL; Kahn SE; Altshuler D; Knowler WC; Florez JC;
Diabetologia; 2007 Dec; 50(12):2451-60. PubMed ID: 17898990
[TBL] [Abstract][Full Text] [Related]
7. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
Florez JC; Jablonski KA; Sun MW; Bayley N; Kahn SE; Shamoon H; Hamman RF; Knowler WC; Nathan DM; Altshuler D;
J Clin Endocrinol Metab; 2007 Apr; 92(4):1502-9. PubMed ID: 17213274
[TBL] [Abstract][Full Text] [Related]
8. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
[TBL] [Abstract][Full Text] [Related]
10. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.
Azen SP; Peters RK; Berkowitz K; Kjos S; Xiang A; Buchanan TA
Control Clin Trials; 1998 Apr; 19(2):217-31. PubMed ID: 9551285
[TBL] [Abstract][Full Text] [Related]
11. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
Yatagai T; Nakamura T; Nagasaka S; Kusaka I; Ishikawa SE; Yoshitaka A; Ishibashi S
Diabetes Res Clin Pract; 2004 Jan; 63(1):19-26. PubMed ID: 14693409
[TBL] [Abstract][Full Text] [Related]
12. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program.
Moore AF; Jablonski KA; Mason CC; McAteer JB; Arakaki RF; Goldstein BJ; Kahn SE; Kitabchi AE; Hanson RL; Knowler WC; Florez JC;
J Clin Endocrinol Metab; 2009 Feb; 94(2):449-55. PubMed ID: 19017751
[TBL] [Abstract][Full Text] [Related]
13. Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program.
Majithia AR; Jablonski KA; McAteer JB; Mather KJ; Goldberg RB; Kahn SE; Florez JC;
Diabetologia; 2011 Oct; 54(10):2570-4. PubMed ID: 21779873
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
15. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Berkowitz K; Peters R; Kjos SL; Goico J; Marroquin A; Dunn ME; Xiang A; Azen S; Buchanan TA
Diabetes; 1996 Nov; 45(11):1572-9. PubMed ID: 8866563
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
17. The Diabetes Prevention Program.
Muniyappa R; El-Atat F; Aneja A; McFarlane SI
Curr Diab Rep; 2003 Jun; 3(3):221-2. PubMed ID: 12762969
[No Abstract] [Full Text] [Related]
18. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
19. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
Kitabchi AE; Temprosa M; Knowler WC; Kahn SE; Fowler SE; Haffner SM; Andres R; Saudek C; Edelstein SL; Arakaki R; Murphy MB; Shamoon H;
Diabetes; 2005 Aug; 54(8):2404-14. PubMed ID: 16046308
[TBL] [Abstract][Full Text] [Related]
20. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
